iSonea (ASX:ISN) will conduct a trial of its second generation AirSonea wireless asthma wheeze monitor that has new software to improve the speed of detection and quantification of wheeze.
The trial will be conducted at a leading American University to expedite its Food and Drug Administration clearance.
Recruitment of patients will start towards the end of September and the trial should be completed by the end of December 2015.
All of iSonea’s products use its proprietary Acoustic Respiratory Monitoring technology and with the exception of AirSonea, have received FDA clearance.
Discussions to monetise the business are continuing with potential partners will continue whilst the trial is being conducted.
